EDL
Evidence Grade D — Primarily preclinical. 22 published studies, mostly animal models. 0 registered clinical trials.
Ovagen is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target liver tissue. Peer-reviewed publications specifically on Ovagen are essentially absent from indexed scientific databases. It has no regulatory approval and no verifiable clinical or preclinical data.
22 published studies: 0 human, 20 animal, 5 in-vitro, 0 reviews
Ovagen has no marketing authorisation from any major regulatory agency. Direct peer-reviewed publications specifically on this compound are essentially absent from indexed scientific databases. Vendor materials cite preclinical studies, but these could not be independently verified.
The inability to locate verifiable peer-reviewed evidence for this specific compound in standard scientific databases represents a significant evidence gap. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Ovagen may influence liver-specific gene expression. However, verifiable peer-reviewed publications on this specific compound could not be confirmed in accessible scientific databases. The proposed mechanisms are based on the broader Khavinson bioregulation framework.
This compound has the weakest evidence base in this batch. Virtually no Ovagen-specific peer-reviewed publications exist in accessible scientific databases. Most evidence is extrapolated from related Khavinson peptides rather than demonstrated for this specific compound. No clinical trials, no confirmed animal studies, no pharmacokinetic data, and no safety data exist for this specific peptide. An unresolved discrepancy between the capsule formulation ingredient and the research peptide sequence raises product identity questions. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
